Published by Josh White on 29th November 2018
(Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Thursday that it will participate in an international multicentre trial, designed to assess the impact of outreach HCV diagnostics and therapy in a pharmacy setting when compared conventional treatment pathways.